News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
259,571 Results
Type
Article (13523)
Company Profile (106)
Press Release (245942)
Section
Business (87909)
Career Advice (460)
Deals (15323)
Drug Delivery (61)
Drug Development (36500)
Employer Resources (49)
FDA (6243)
Job Trends (6179)
News (149883)
Policy (14001)
Tag
Academia (435)
Africa (312)
Alliances (23062)
Alzheimer's disease (334)
Approvals (6232)
Arizona (36)
Artificial intelligence (47)
Asia (19679)
Australia (2537)
Bankruptcy (143)
Best Places to Work (4242)
Biosimilars (32)
Biotechnology (44)
Breast cancer (25)
C2C Services and Suppliers (10606)
California (682)
Canada (475)
Cancer (189)
Career advice (402)
Cell therapy (30)
China (75)
Clinical research (30148)
Collaboration (78)
Compensation (35)
Connecticut (30)
COVID-19 (742)
Data (159)
Diabetes (35)
Diagnostics (1212)
Drug pricing (53)
Earnings (31193)
Employer resources (43)
Europe (38513)
Events (36378)
Executive appointments (111)
FDA (6351)
Florida (94)
Funding (58)
Gene therapy (47)
GLP-1 (271)
Government (1257)
Healthcare (3510)
Hotbed/Location (177948)
Illinois (79)
Indiana (66)
Infectious disease (751)
Inflammatory bowel disease (44)
Interviews (57)
IPO (5787)
Job creations (2047)
Job search strategy (371)
Kansas (49)
Layoffs (165)
Legal (3401)
Lung cancer (34)
Manufacturing (65)
Maryland (107)
Massachusetts (608)
Medical device (1255)
Medtech (1257)
Mergers & acquisitions (9504)
Metabolic disorders (123)
Minnesota (43)
Neuroscience (404)
New Jersey (291)
New York (200)
NextGen Class of 2024 (1578)
Non-profit (589)
North Carolina (237)
Northern California (291)
Obesity (79)
Ohio (35)
Opinion (107)
Patents (44)
Pennsylvania (208)
People (28299)
Pharmaceutical (61)
Phase I (7838)
Phase II (12743)
Phase III (11455)
Pipeline (65)
Podcasts (37)
Policy (40)
Postmarket research (1400)
Preclinical (3137)
Radiopharmaceuticals (115)
Rare diseases (60)
Real estate (2627)
Regulatory (9737)
Research institute (562)
Resumes & cover letters (55)
South America (497)
Southern California (307)
Startups (1626)
Texas (94)
United States (3039)
Vaccines (99)
Virginia (26)
Washington State (53)
Weight loss (64)
Date
Last 7 days (232)
Last 30 days (884)
Last 365 days (13116)
2024 (9880)
2023 (14245)
2022 (19564)
2021 (20081)
2020 (19035)
2019 (14890)
2018 (11713)
2017 (13894)
2016 (13134)
2015 (15476)
2014 (12419)
2013 (10593)
2012 (11395)
2011 (11924)
2010 (10890)
259,571 Results for "eton pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the quarter ended March 31, 2024.
May 9, 2024
·
10 min read
Business
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024.
April 29, 2024
·
1 min read
Press Releases
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
October 3, 2024
·
8 min read
Policy
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the submission of a New Drug Application to the U.S. Food and Drug Administration for approval of ET-400, Eton’s proprietary patented formulation of hydrocortisone oral solution.
April 30, 2024
·
3 min read
Business
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter and year ended December 31, 2023.
March 14, 2024
·
11 min read
BioMidwest
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference - May 01, 2024
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows.
May 1, 2024
·
1 min read
Business
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024.
February 29, 2024
·
1 min read
Business
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 8, 2024
·
12 min read
BioMidwest
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq: ETON) today announced that the United States Patent and Trademark Office (“USPTO”) has granted the Company’s U.S. Patent Application No. 18/113,458, which covers the Company’s ET-400 product candidate’s proprietary formulation of oral liquid hydrocortisone.
February 21, 2024
·
2 min read
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
RELIEF THERAPEUTICS Holding SA announced it has granted an exclusive license to Eton Pharmaceuticals, Inc. for the commercialization of GOLIKE ® family of products in the United States.
March 22, 2024
·
6 min read
1 of 25,958
Next
